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ABSTRACT
Background: Increased burden of multidrug resistant Enterobacteriaceae (MDRE)causing
urinary tract infection (UTI)compounded by harboring carbapenemase producing strainsbecomes
a serious threat to public health.Carbapenemase producing Enterobacteriaceae (CPE)expresses
enzymes thatcan break down carbapenems. Prevalence of MDRE in different part of the world is
increasing, but data about the incidence of CPE in is not yet documentedin Ethiopia.
Objective: The aim of the study was to assess the prevalence and risk factors of MDR and CPE
among patients with UTIs.
Methods:A cross sectional study was conducted among 442 symptomatic UTI suspected
patients atthe University of GondarHospital from February to May 2014. Systematicrandom
sampling techniquewas used to select the participants. Data onsocio-demographiccharacteristics,
clinical informationand possible risk factors werecollected using structured questionnaire. Mid-
stream urine samples were collected and processed to characterize bacterial isolates. Disk
diffusion method was used to determine the antibiotic susceptibility patterns of isolates. In this
particular study, CPE isolates were detected usingCHROMagar KPC medium.Data were entered
and analyzed using SPSS version 20. P-value <0.05 were considered as statistical significant.
Results: A total of 442 patients with mean age of 37.1 years were included in this study and the
majorities were females (63.8%). From 183 (41.4 %) of patients, 183 Enterobacteriaceae
isolates were identified; of which,160 (87.4%) were MDRE;the principalisolates were
E.coliandK. pneumoniae.Moreover, 5 (2.73%) of isolates were found to be carbapenemase
producers, namely E.coli (2), K. pneumoniae (2), and E. aerogenes (1). Significant drug
resistances were observed among CPE compared to other MDRE, low resistance rates were
noted to ciprofloxacin (20%). Being female (OR 4.46; P = 0.018), age (OR 1.08; P = 0.001),
hospitalization(OR 5.23; P = 0.006), and prior antibiotic use (OR 3.98; P = 0.04) were associated
risk factors with MDRE.
Conclusion and recommendations:Increased prevalence of MDRE and incidence of CPE were
indicated in this study. Attributingrisk factors for MDRE were found to be sex (female), age,
hospitalization, and history of antibiotic therapy. Therefore, efforts should be directed to
reducepatient hospital stay and to maximize rationaluse of drugs. Additional and vigorous
investigation especially on CPE should be encouraged.
Key words: Carbapenemase, Enterobacteriaceae, Multidrug resistant, Urinary tract infection
11. INTRODUCTION
1.1. Background
Urinary tract infection (UTI) is the presence of bacteria (bacteriuria) in urine and witha growth
of a single pathogen ≥105 colony forming units (cfu)/ml from a properly collected mid-stream
urine sample. Symptoms of UTIsare dysuria, urgency and frequent urination, along with
malodorous and/or cloudy urine. Signs of infection include the presence of blood (hematuria) or
white blood cells (pyuria) in urine (1).
Urinary tract infections are one of the most common infectious diseases ranking next to upper
respiratory tract infection. Urinary tract infections are often associated with significant morbidity
and mortality. Worldwide, about 150 million people are diagnosed with UTI each year, costing
the global economy in excess of 6 billion dollars(2). In developing countries, including Ethiopia,
the facilities for urine culture and antimicrobial susceptibility testing are still not sufficiently
available, leading to improper diagnosis and irrational antibiotic treatment  of UTI, which
expedites the emergence of multidrug resistant (MDR) strains (3).Gram negative bacteria,
especially the family Enterobacteriaceaeare the common cause of both community and hospital
acquired UTIs. Escherichia coli andKlebsiella pneumoniae are most commonlyimplicated
amongpatients with UTI(4, 5).
Enterobacteriaceaespread easily between humans by hand carriage as well as contaminated food
and water and have a propensity to acquire genetic material through horizontal gene transfer,
mediated mostly by plasmids and transposons, which are most important factors, for emergence
of MDRamong these bacteria. Theincrease rate of antibiotic resistance among
Enterobacteriaceae has posed challenges in choosing empiric regimens, especially when the
infections are caused by  multidrug resistant Enterobacteriaceae(MDRE)(6).
Previously, the emergences of MDR among Enterobacteriaceaewere mainly due to the
production of enzymes, such as pencillinases, cephalosorinases, andextended spectrum β-
lactamase (ESBL). However, recently carbapenemase production is one of the main mechanisms
in the occurrence of drug resistance in the family ofEnterobacteriaceae.Carbapenemase
2producing Enterobacteriaceae (CPE) are a family of organisms that are difficult to treat because
they have high levels of resistance to antibiotics. Klebsiellapneumoniae and E. coli are members
of Enterobacteriaceae, which capable of break down all -lactam agents including carbapenems
and make it ineffective. Carbapenem such as imipenem, meropenem, ertapenem, &doripenem
are considered as the last resort antibiotics to treat ESBL producing Enterobacteriaceae(7, 8).
A large variety of carbapenemases has been identified in Enterobacteriaceaebelonging to 3
classes of β-lactamases: the Ambler class A, B and D. In class A, Klebsiella
pneumoniaecarbapenemase (KPC) are encoded by the blaKPC gene, which is located within Tn3-
type transposons, Tn4401, and is capable of inserting into diverse plasmids of gram negative
bacteria, Enterobacteriaceae in particular. In class B, Metallo-beta-lactamases (MBL) includes
Imipenemase(IMP), Verona integron encoded metallo-beta-lactamase (VIM) and the recently
described New Delhi metallo-beta-lactamase (NDM- 1). Imipenemase, VIM and NDM-1 are
encoded by genes located within integron elements, capable of inserting in to various types of
plasmid. In class D, Oxacillin hydrolyzing metallo-β-lactamases (OXA-48) encoded by blaOXA-
48, which shows relatively low carbapenem resistance(6).
Infections caused by CPEmost commonly occur among patients who are receiving treatment for
other conditions. Patients whose care requires devices like mechanical ventilators, urinary
catheters, or intravenous catheters, and patients who are taking long courses of certain antibiotics
are most at risk for infections caused by MDR strains.likewisepatients admitted to critical care
units for treatment of acute emergencies and chronic diseases are especially vulnerable to get
these infections because of the presence of MDR strains in the environment and selective
pressure on them due to overuse of antibiotics(9).
1.2. Statement of the problem
Multidrug resistantis now emerging increasingly in Enterobacteriaceae; this is mainly due to
combined effect of drug resistance mechanisms, such as pencillinases, cephalosporinases
(ESBL), and carbapenemases. Following spread of MDR strains,especiallyESBL producing
Enterobacteriaceae, which can hydrolyzealmost all β-lactam drugs except carbapenem,
drivesenhanced consumption of carbapenems and other broad spectrum antibiotics, which in turn
promotethe occurrence of new drug resistance mechanisms. As a result, due to the occurrence of
3selective pressure carbapenem resistant strains mainly mediated by carbapenemase
productionemergedacross the globe.The current and extensive worldwide spread in MDRE is an
important source of concern since these carbapenemases producing strains capable of break
down both β-lactams and non-β-lactam drugs(10, 11).
Currently, increased burden of MDRE causing UTI compounded by harboring carbapenem
resistance genesmainly among E. coli and K. pneumoniaeincreasingly emerged(6).These strains
become a serious threat to public health, associated with high mortality rates and have the
potential to spread widely. Infections are difficult, and in some cases impossible to treat and have
been associated with mortality rates up to 50%. Due to the movement of patients throughout the
health care system, if CPE is a problem in one facility, then typically they are a problem in other
facilities in the region as well.Carbapenemase producing Enterobacteriaceae are mostly endemic
in specific geographical regions, but reports of their spread into other geographical locations are
point of grave concern these days(12).
Carbapenemase producing Enterobacteriaceaeincreasingly reported in different part of the world.
Class A includes KPC is clinically and epidemiologically the most important enzyme. Klebsiella
pneumoniae carbapenemase majorly isolated among nosocomial K. pneumoniae isolates, but
they have been reported in other Enterobacteriaceaeisolates. Plasmid encoded KPCs, first
demonstrated in 2001 in North Carolina, subsequently become endemic in many states of USA.
Moreover, it rapidly disseminated to different countries like, France, Israel, Greece, Colombia,
and china. Outbreak of KPC also documented in many European countries, South America,
India. At the first time the outbreak of KPCs also reported in a few African countries, such as
South Africa, Nigeria(6, 13).
In class B, IMP and VIM were first identified in 1990s from Pseudomonas isolate from Japan
and Italy respectively. Subsequently, these enzymes gradually expressed in a number of
Enterobacteriaceaegenera. Both VIM and IMP now are endemic in Greece, Italy, Spain, Taiwan,
and Japan, although outbreaks and increasing reports of the isolates have come from Europe.
Cases with bacteria expresses IMP and VIM also noticed in many other countries, USA, and
other South American countries. Besides, NDM-1 containing Enterobacteriaceaehad also been
4reported in every continent of the world, direct link to the Indian subcontinent (India, Pakistan,
and Bangladesh) was established most of these cases. It also reported in some African countries,
like Morocco, Kenya, and South Africa(6, 13).
Class D includes OXA carbapenemases which are mostly found in Acinetobacter spp., although
OXA-48 occurs in Enterobacteriaceae. High level of carbapenem resistant occurs only when
OXA enzymes are co-expressed with ESBLs and porin resistance factors and mostly recovered
from K. pneumoniae and E.coli, reported across Europe, the Southeastern Mediterranean
region, and Africa(6, 14).
Emerging Resistance to carbapenems and their spread all over the world emphasizes the need to
evaluate the burden of CPE. There is growing evidence of increasing prevalence of MDRE in
different part of the world(15); however, as far as our concern of literature review information
regarding the prevalence of CPE is not yet documentedand this is presumed to be first of its kind
in Ethiopia.Therefore, this study was aimed to evaluate the prevalence, associated risk factors for
CPE and MDREamong patients with UTI at the University of Gondar Hospital, Northwest
Ethiopia.
52. LITERATURE REVIEW
2.1. Prevalence of multidrug resistant and carbapenemase producing Enterobacteriaceae
β-lactamase production is the most common mechanism of β-lactam drug resistance in gram
negativebacteria. The rapid dissemination of MDRE has been increasingly reported and
constitutes a major public health concernin both developing and developed world.For instance
increased rate of MDRE were reported from American studies, Chicago(19.06%), E.coli the
main MDR isolate (76%), followed by Proteus mirabilis and Citrobacter spp (6%), and K.
pneumoniae (5%) (16). In Europe, similar finding from Italy and Belgium, the prevalence of
MDRE were 62%; in both studies K.pneumoniae and E.coli were the mostprevailing  MDR
strains isolated(17, 18).
Multidrug resistant Enterobacteriaceaehave also a major public health threatin developing
countries. According to study in Nepal in 2012 among 202 Enterobacteriaceae isolates, 40.1%
were MDRE, Citrobacter spp were the principal MDR isolate (72%) followed by E. coli
(38.2%)(19). However, in a 2013 another study from Nepal showed that increased prevalence of
MDRE (64.04%)was reported. E.coli (74%) and K.pneumoniae (44%) were the predominant
MDR isolates(20). Besides, in Mozambique, 88.2% of isolates of Enterobacteriaceaewere found
to be MDR strains(21). A multicenter study in Senegal demonstrated that increased prevalence of
antimicrobial resistance observed among Enterobacteriaceaeuropathogens. The overall resistance
rates of ampicillin, amoxicillin, amoxicillin-calvulanic acid, naldixic acid, fluoroquinolones and
cotrimoxazole were77.3%, 34.7%, 14.7%, 13.3% and 55%, respectively. Among member of
Enterobacteriaceae, 89% of drug resistances were implicated in E. coli and K. pneumoniae(22).
Various research findings claimed that increased trendsin the prevalence of MDR among
Enterobacteriaceae also a major concernin Ethiopia. Particularly in Gondar the prevalence of
MDRE increased from time to time, i.e. 2002 the prevalence of MDR strains were 68%(23), the
magnitude increased to 85.5% (2007)(24) and 93.5% (2013)(25). Moreover; tremendous
prevalence of MDR strains also reported in other parts of Ethiopia, in Dessie (74.6%) (26),
Bahirdar (95.6%) (27), and Jimma (100%) (28). In all studies E. coli and K.pneumoniae were the
principal MDR isolates among uropathogens.
6In the recent years, there is an increase trend of resistance to carbapenem among
Enterobacteriaceae in clinical isolates. According to data from the European Antimicrobial
Resistance Surveillance Network (EARS-Net) showed that, the rates of CPE (K. pneumoniae)
increased in most European countries. Greece, Cyprus and Italy reported resistance rates of
43.5%, 17.0% and 1.3% respectively (29-31). Likewise, based on center for disease control and
prevention report on health care associated infections the overall prevalence of CPE (KPC) rising
from less than 1% in 2000 to 8% in 2007 (15).  Particularly, in France 6, 26 and 13 CPE episodes
were reported in 2009, 2010 and the first four months of 2011, respectively (32).
A summary data from EARS-Net surveillance study (2011) starting from 2008, the numbers of
confirmed CPE increased dramatically: 23 in 2008, 73 in 2009, 333 in 2010, and 561 in 2011.
Most producers were Klebsiella (80%), mainly K. pneumoniae, followed by E. coli (10%) and
Enterobacter (8%), with the remaining 2% comprising occasional isolates of Citrobacter,
Morganella, Providencia, Raoultella and Serratia. The enzymes produced included KPC (62%),
NDM (14%), VIM (12%), and OXA-48-like (9%) and IMP (2%) types(33).
Carbapenemase producing Enterobacteriaceae are the principal clinical isolates from patients
with UTI. A four year study from Ontario, Canada; demonstrated that from known 73 CPE
clinical isolates, 46.6%, 32.9%, 5.5%, 2.75%, 2.75%, 2.75%, 1.4%, 1.4%, & 4.1% were
recovered from urine, rectal swab, wound, blood, sputum, intraperitoneal fluid, bone, skin swab
& other body samples respectively (34). Besides, similar isolation rate of carbapenemase
producing K. pneumoniae detected from patients with UTI in Italy and it was 47.5% (35).
According to a study, from 4564 screened Enterobacteriaceae isolates, 158 (3.5%) were
carbapenemase producing strains. K. pneumoniae, E.coli, K. oxytoca and Enterobacter spp had
found expressing different class of carbapenemase (36). Moreover, comprehensive
epidemiological study in United Kingdom, India and Pakistan showed that about 4.5% of isolates
were CPE (37). In another study the overall prevalence of CPE had been found 10.9%, K.
pneumoniae (90%) and E.coli (10%) were most important isolates (38). A finding from United
States of America, the prevalence of CPEwas found to be 21% (39).
7In Asia, increase prevalence of CPE was also reported, in India Among 392 isolates of
Enterobacteriaceae and gram negative non-fermentative bacilli, carbapenemase production was
detected in 21 (5.4%) isolates (40).Besides, anotherfinding from India showed that 12.9% of
isolates were CPE (41). Finding from Pakistan, the presence of CPE was investigated using
chromogenic culture media, 13isolates (8·6%) were found to be NDM-1 producing
Enterobacteriaceae (42). In Bangladesh, among the isolates, 4.8% were found to be CPE (43).
Increase prevalence of CPE has been also reported from 64 isolated strains, 13 (20.3%)mainly K.
pneumoniae(44), in the same year, another study in Iran relatively low prevalence of CPE were
also documented (14.7%) (45). While, a study in Taiwan has shown that decreased incidence of
CPE (2.5%) was reported compare to other studies in this continent (46).
Due to lack of sufficient surveillance study in Africa, only few studies are reported.  In Kano,
Nigeria the prevalence of CPE were reported to be 14%. High carbapenemase expression
detected in K. pneumoniae followed by Proteus spp &E.coli (47). Another finding from  Nigeria,
extremely high prevalence of CPE, reported i.e. 33.5% (67/200) isolates were found to be
carbapenemase producing strains; of which, E. coli accounts(31.3%), followed by Proteus spp
(21.6%) and K. pneumoniae (14.3%) (48). A study in Morocco has shown the overall prevalence
of CPE were 13/463 (2.8%). These were K.  pneumoniae (69.2%), E .coli(23%) and K. oxytoca
(7.8 %), showed 100% resistant to AMC, CTX, CTR, and SXT; 85%resistant to CIP and
54%susceptible to GEN(49). From November 2008 through October 2009, 11 CPE isolates (8
Klebsiella pneumoniae, 1 Escherichia coli, 1 Enterobacter cloacae, and 1 Enterobacter
sakazakii) were identified at the Institute Pasteur (Dakar, Senegal) (50). Furthermore, a study in
Kenya from archival collected MDR K. pneumoniae strains, seven carbapenem resistant
carbapenemase (NDM-1) were isolated from urine, the isolates were resistant to all b-lactam
drugs including carbapenems(51).
2.2. Risk factors of multidrug resistant and carbapenemase producing Enterobacteriaceae
Several factors are associated with the rapid increase in the prevalence of MDRE. Based on a
retrospective study, age,  gender, diabetes mellitus, obstructive uropathy,  health care associated
risks (chronic indwelling urinary catheters, healthcare exposure, including hospital stay for at
least 48 hours, nursing home or long-term carefacility, residence, regular hemodialysis clinic
8visits or urological procedures within the past 3 months), prior UTI, and prior use of any
antibiotics,  were associated with MDRE infections(16).
Rapid spread and increase prevalence of CPE attributed by various factors. According to  a
systematic review by experts from European center for disease prevention and control(ECDC);
risk factors found to be associated with colonization or infection with CPE were: advanced age,
prior antimicrobial use, length of stay (time at risk); severity of illness; mechanical ventilation;
admission to the intensive care unit (ICU), high procedure score; presence of wounds, transfer
between hospital units within the same hospital, chronic disease(acquired immuno-deficiency
syndrome, chronic heart disease, chronic lung disease); diabetes mellitus; pregnancy; prior
surgery; prior hospital stay; presence of a biliary/urinary catheter, previous UTI and recent
transplantation(16, 52, 53).
Furthermore, several investigators have also evaluated the factors associated with increased risk
for acquisition of CPE. A retrospective case control study has shown that the independent risk
factors for infection with CPE were prior fluoroquinolones use, previous receipt of a carbapenem
drug, admission to the ICU, and history of antibiotic use(54). Similarly finding from Israel,
independent predictors of subsequent CPE clinical specimens were: admission to the ICU,
hospital stay, having  urinary catheter, receipt of antibiotics, and diabetes mellitus(55).
9Figure 1: Conceptual framework for factors associated with MDRE and CPE.
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3. SIGNIFICANCE OF THE STUDY
The aetiology of UTI and the antibiotic resistance of uropathogens have been changing over the
past years, both in community and health care associated infections. Current knowledge on the
burden and antimicrobial susceptibility pattern of the Enterobacteriaceae isolatesis essential for
appropriate therapy, since those groups of bacteria are the main cause of UTIs and possess
several mechanisms to dismantle currently available antibiotics including carbapenems.
This study is important to provide baseline and crucial information regarding to MDR and CPE
isolates among UTI patients. Hence policy makers, health administrators and other stake holders
can be benefited to design and implement appropriate intervention mechanisms to combat the
incidence of infections caused by resistant strains in particular. Furthermore, asa result of this
finding health care providers will enforce to follow empirical treatment rules, adopt and utilize
standard protocols in the identification of CPE as routine activities.
Moreover, there are few studies conducted in the continent of Africa, based on the knowledge of
literature review no published findings were found on the aetiology and resistance pattern of
community and hospital acquired UTIs caused by CPE in Ethiopia. Therefore, the purpose of this
study was to determine the prevalence, associated risk factors of carbapenemase producing and
MDRE among patients with symptomatic UTIs at the University of GondarHospital, Northwest
Ethiopia.
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4. OBJECTIVES
4.1. General objective
 To assessthe prevalence and risk factors ofmultidrug resistant andcarbapenemase
producing Enterobacteriaceaeamong patients with symptomatic urinary tract
infection, University of Gondar Hospital.
4.2. Specific objectives
 To determine the prevalence of multidrug resistant Enterobacteriaceae
 To determine the prevalence of carbapenemase producing Enterobacteriaceae
 To identify risk factors relating with the occurrence of multidrug resistant
Enterobacteriaceae
 To identify risk factors relating with the occurrence of carbapenemase producing
Enterobacteriaceae
12
5. MATERIALS AND METHODS
5.1. Study area
The study was conducted at the University of Gondar Hospital. The University of Gondar
Hospital is a tertiary level teaching hospital which is located in Gondar town, 750 km from
Addis Ababa in the Northwest Ethiopia. The hospital provides surgical, medical, pediatric,
gynecologic, obstetric, and ophthalmologic services to the community for over 5million
inhabitants. The hospital has an accredited (three star) referrallevel laboratory with 7 sections
and a separate reception room. Microbiology section is one of the principal area, it is estimated
that 9,600 samples delivered per annum to this working area. In this section, culturing is one of
the main activities, mainly applicable for bacterial isolation and identification.
5.2. Study design and period
A laboratory based cross-sectional study was conducted from Februaryto May 2014.
5.3. Population
5.3.1. Source population
Source of population was all patients with suspected UTI seeking treatment, at the University of
Gondar Hospital.
5.3.2. Study population
Patients with symptomatic suspected UTIs, whowere accessed at the time of study period at
theUniversity of Gondar Hospital.
5.4. Inclusion criteria
Patients with symptomatic UTIwere involved in the study
5.5. Exclusion criteria
Patients with asymptomatic UTI and patient on antibiotics (since the last 7 days)were excluded
from the study.
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5.6. Study variables
5.6.1. Independent variables
Age, sex, history of travel to abroad, prior antibiotic use in the past 6 months, history of UTI in
the past 12 months, history of hospitalization in the past 12 months, ICU admission in the last 6
months, surgery in the last 6 months, history of urinary catheter usage in the past 12 months,
presence of mechanical ventilator in the past 12 months, pregnancy and history of hemodialysis
in the past 3 months.
5.6.2. Dependant variables:
 Presence/Absence of MDRE
 Presence/Absence of CPE
5.7. Sampling technique and Sample size determination
Systematic random sampling technique was utilized. Sample size was determined by using the
prevalence of 50%. So that the final sample size calculated by using singlepopulation proportion
formula.
N =
( / ) ( )
, where
 N is the minimum sample size
 Z α/2 is the standard normal deviation corresponding the specified  of total Population, at
95% confidence level = 1.96
 p is the prevalence = 0.5; 1-p = 0.5, and d is the desired degree of accuracy = 0.05
So that a total of 442 study participants with symptomatic UTIwere enrolled, considering 15%
contingency.
5.8. Sampling procedure
A total of 442 study participants were selected by using systematic sampling interval (K),
calculated by using the anticipated patient (UTI) flow in hospital; approximately 420
patients/month. So that data collection planned for 3 months: K= N/n, 1260/442 = 3. Then, the
first three individuals were selected;of whom one individual was included in the study randomly.
Finally, every 3rd individual who had visited the hospitalwas selected to participate in the study.
14
5.9. Operational definition
Hospital acquired infection: infection acquired during hospital stay and that appears within 48-
72 hours after admission in the hospital and the patient was not incubating this infection at the
time of admission.
Multidrug resistant(MDR): defined as resistance to two or more different antibioticagents.
5.10. Data collectionand processing
5.10.1. Questionnaire
Important variables of the study were addressed by using interviewer administered structured
questionnaire (mainly adopted from ECDC survey, 2013) having three parts; the first contains
socio-demographic information, the second part comprises clinical data and the 3rd part contains
possible risk factors for CPE and MDRE(Annex-I).The questionnairewas translated to Amharic
and re-translated back to English to make the reliability of the instrument. Before undertaking
the data collection the instrument was tested taking 5% eligible for the feasibility of the
questionnaires. Data were collected by two trained data collectors, experiencednurse/health
officerand medical laboratory profession, previous experience and living and speaking local
language. Data were gathered mainly through patient interview and revising medical records.
5.10.2. Urine specimen
Urine specimen was collected from each patient, after instructing how to collect a clean catch
mid-stream urine specimen(Annex-II)(56). Accordingly, about 20 ml urine specimen was
collected in a sterile screw-capped, wide-mouth container and labeled with the unique sample
number, date and time of collection. Urine from infants and severely ill patients were collected
by health professionals.The specimens were delivered to bacteriology laboratory within 30
minutes of collection for culture and microscopic examinations. The investigator and a trained
laboratory technician/ technologist had undertaken activities in each stage of urinalysis (pre-
analytical, analytical and post- analytical) to gather the intended laboratory information.
5.10.3. Isolation and Identification of Enterobacteriaceae
Urine specimens obtained from the patients weredirectly inoculated on 5% Sheep blood agar
(Annex-III). Culture plates wereincubated at 37ºC for 24 hours, after incubation urine culture is
considered as positive, if it contains >105 cfu/ml of clean catch mid-stream urine. After gram
staining pure colonies (convex, grey, smooth/mucoid)were sub-cultured on MacConkey agar
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(Annex-III) for further identification. Enterobacteriaceae from positive urine cultures were
identified by their characteristic appearance on the media, gram staining reaction, by the pattern
of biochemical profiles using standard procedures.Biochemical tests such as indole production,
sugar fermentation, H2S and gas production, citrate utilization, motility test, urease test, oxidase,
were used to identify Enterobacteriaceae isolates (56).
5.10.4. Antimicrobial susceptibility testing
All identified clinical strains were subjected to in vitrosusceptibility testing using Kirby Bauer
disk diffusion method as described in clinical and laboratory standards institute (CLSI)
guidelines and interpreted accordingly (57).From a pure culture 3-5 selected colonies of bacteria
were taken and transferred to a tube containing 5 ml sterile nutrient broth (Oxoid) and mixed
gently until a  homogenous suspension was formed and incubated at 37oC until the turbidity of
the suspension become adjusted to a McFarland 0.5. A sterile cotton swab was used and the
excess suspension was removed by gentle rotation of the swab against the surface of the tube.
The swab was then used to distribute the bacteria evenly over the entire surface of Mueller
Hinton agar (Annex-III) (pH 7.2-7.4) (Oxoid) (57).
After inoculation, the following antibiotic disks (Oxoid)wereequidistantly placed on these plates
and gently pressed onto themedium with the help of sterile forceps to ensure complete contact
with the agar surface.:cefotaxime (CTX; 30µg),ceftriaxone (CTR; 30µg), cefepime (CPM;
30µg), ceftazidime (CAZ; 30µg), cefpodoxime (CPD: 30µg), ciprofloxacin (CIP; 5µg),
tetracycline (TE; 30µg), chloramphenicol (C; 30µg), amoxicillin-calvulanic acid (AMC; 30µg),
naldixic acid (NA; 30µg),gentamycin (GEN; 10µg), ampicillin (AMP; 10µg)and trimethoprim-
sulfamethoxazole (SXT; 25µg). The criteria used to select the antimicrobial agents are based on
their availability and frequent prescriptions for the management of UTIs. The plates were then
incubated at 37oC for 24 hours. Diameters of the zone of inhibition around the discs was
measuredusing antibiotic zone scale (HiMedia), and the isolates were classified as susceptible,
intermediate and resistant(57).
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5.10.5. Carbapenemase testing
After antimicrobial susceptibility testing, each bacterial isolate considered as MDRE was sub-
cultured on CHROMagarTMKPC agar(Annex-III)to determine carbapenemase production. After
overnight incubation (18-24hr), carbapenemase producing isolates were assessed by visualizing
colonies with typical coloring characteristics.  Carbapenemase producing E. colideveloped dark
pink to reddish colony features, while other Enterobacteriaceae isolate produced metallic blue
colonies(58).
5.10.6. Quality control
The reliability of the study findings were guaranteed by implementing Quality control measures
throughout the whole process of the laboratory work. All materials, equipment and procedures
were adequately controlled. Culture media were tested for sterility and performance. Pre-
analytical, analytical and post-analytical stages of quality assurance that are incorporated in
standard operating procedures of the microbiology laboratory of University of Gondar hospital
were strictly followed. International control strains; E.coli®ATCC 25922(positive control) and S.
aureus ATCC®25923 (negative control)were used to control the performance of media. To
standardize the inoculum density of bacterial suspension for a susceptibility test, 0.5 McFarland
standardswas used(57, 58).
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Figure 2: Flow chart explaining the experimental work.
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5.11. Data Analysisand interpretation
Data were collected, summarized, tabulated and analyzed using SPSS version 20 software and
resultswere presented through tables, pie charts and graphs. Associationswere measured using
chi-square test, binary logistic regression. P-values< 0.05 were considered as statistically
significant.
5.12. Ethical Considerations
The study was initiated after ethical approval by Research and Ethics committee of School of
Biomedical Laboratory Sciences. Subjects were recruited after getting written informed consent.
Only those who are volunteerswererequested to give samplesand to answer intended questions.
Participantshad full right to continue or withdraw from the study.  For each confirmed case, the
responsible clinician of the patient was informed and gets their treatment timely. Information
obtained in each course of the study was kept confidential.
5.13. Result dissemination
The result will be disseminated to University of Gondar, College of Medicine and Health
Sciences, School of Biomedical and Laboratory Sciences, Department of Medical Microbiology
and other concerned bodies. In addition, the study will be presented to the health staffs in health
facility where the study is conducted. Moreover the finding of the study will be also presented to
GCMHS staffs and students. Finally a manuscript will be prepared and submitted for publication
in areputable journal.
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6. RESULTS
6.1. Socio-demographic characteristics
A total of 442 patients with symptomatic UTI were included in this study to investigate
prevalence and risk factors of MDRE and CPE. The majority of the participants were females
282 (63.8 %). Themean age of patients was 37.05+10.5 years, 86 (19.5%) of the patients were
younger than 16 years, and 73 (16.5%) were older than 60 years. Two hundred fifty two (57.0%)
of patients were residents of rural areas, and majority, 286 (64.7%) of study participants had
educational level of elementary school and below (Table 1).
Table 1: Socio-demographic characteristics of study participants: University of Gondar Hospital,
February to May 2014 (N = 442).
Variables Frequency Percentage
Sex Male 160 36.2
Female 282 63.8
Age <15 86 19.5
16-30 84 19
31-45 101 22.9
46-60 98 22.2
>61 73 16.3
Residence Rural 252 57
Urban 190 43
Educational status Illiterate 196 44.3
Primary school 90 20.4
Secondary school 69 15.6
Diploma and Above 87 19.7
Sender of the patient Outpatient 212 48
Inpatient 230 52
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6.2. Prevalence of MDRE and CPE isolates among study participants
Among study participants, 183 (41.4%) patients, who had positive urine culture with a single
non-duplicate isolates of Enterobacteriaceaewere identified. The majority of isolates were E.coli
112 (61.2%) followed by K. pneumoniae29 (15.8%) and E.aerogenes 13(7.1%) (Figure3). The
isolates were tested for antimicrobial susceptibility, 160 (87.4%, 95%CI; 82-92.3%)of
themshowed resistance to two or more antibiotics. Among MDR strains, only 1 (0.6%) isolate
was resistant to 2 antibiotics, the rest 159 (99.4%) were resistant to three or more antibiotics
(Table 2). From MDRE isolates, 106 (66.3%) were identified from female patients and 37
(23.1%) of isolates were indicated in patients with age group from 31 – 45 years (Table3).
Figure 3: Frequency of Enterobacteriaceae isolatesamong study participants: University of
Gondar Hospital, February to May 2014.
E. coli, 112(61.2%)K.pneumoniae, 29(15.
8%)
K.
ozaenae, 8(4.4%)
K. oxytoca, 3(1.6%)
E.
aerogenes, 13(7.1%
)
E. cloacae, 3(1.6%)
P. mirabilis, 5
(2.7%)
P. vulgaris, 4
(2.2%)
Citrobacter
spp, 6(3.3%)
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Table 2: Multidrug resistance pattern of Enterobacteriaceae among study participants: University ofGondar Hospital, February to May
2014.
Isolates Degree of resistance MDR isolates
(>R2)R0 R1 R2 R3 R4 R5 R6 R7 R8 >R9
E. coli(N = 112) 2
(1.8)
6
(5.4)
__ 5
( 4.5)
28
(25)
24
(21.4)
32
(28.6)
9 (8.0) 4
(3.6)
2
(1.8)
104
(92.9)
K. pneumoniae(N = 29) __ 1
(3.4)
__ 3
(10.3)
5
(17.2)
6
(20.7)
4
(13.8)
3
(10.3)
4
(13.8)
3
(10.3)
28
(95.6)
Other Klebsiella spp.(N =
11)
__ 2
(18.2)
__ __ __ 3
(27.3)
3
(27.3)
1
(9.1)
1
(9.1)
1
(9.1)
9
(81.8)
Enterobacter spp. (N =
16)
2
(12.5)
1
(6.3)
__ 1
(6.3)
2
(12.5)
3
(18.8)
5
(31.3)
1
(6.3)
__ 1
(6.3)
13
(81.3)
Citrobacter spp. (N = 6) 1
(16.7)
__ 1
(16.7)
__ 1
(16.7)
__ 2
(33.3)
__ 1
(16.7)
__
5
(83.3)
Proteus spp. (N = 9) 5
(55.6)
3
(33.3)
__ ___ ___ 1
(11.1)
___ __ __ __ 1
(11.1)
Total (N = 183) 10
(5.5)
13
(7.1)
1
(0.5)
9
(4.9)
36
(19.7)
37
(20.2)
46
(25.1)
14
(7.7)
10
(5.5)
2
(1.1)
160
(87.4)
Note: Data are in number (%) unless otherwise indicated.
R0: susceptible to all antibiotics, R1-8: resistance to 2, 3, 4, 5, 6, 7, and 8antibiotics, >R9: resistance to 9 or more antibiotics,
>R2: resistance to 2 or more antibiotics.
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Table 3: Distribution of MDRE and CPEper socio-demographic characteristics among study
participants: University of Gondar Hospital, February to May 2014.
Characteristics MDRE  isolates p-value CPE isolates p- value
Yes No Yes No
Sex Female 106 12 0.187 4 102 0.509
Male 54 11 1 53
Age group <15 27 16 <0.001 1 26 0.277
16 - 30 31 4 0 31
31 – 45 37 2 3 34
46 – 60 33 1 1 32
>61 32 0 0 32
Residence Rural 85 16 0.138 0 85 0.016
Urban 75 7 5 70
Educational status illiterate 70 14 0.331 2 68 0.510
Primary school 32 5 1 31
Secondary school 29 2 2 27
Diploma and above 29 2 0 29
Sender of patient Outpatient 67 13 0.185 1 66 0.314
In patient 93 10 4 89
The distribution of the bacteria in patients’ with and without MDRE isolates is shown in Table 4.
E.coli was significantly more common in patients with MDRE than those with non-MDRE
infections (65 versus 34.8%; = 0.020), while P. vulgaris(0.63% versus 13%; P = 0.000) and
E.cloacae (0.63% versus 8.7%; p = 0.004) were significantly more common in patients with non-
MDRE than those with MDRE infections. Moreover; K. oxytoca and P. mirabilis were only
identified in patients with MDRE and non-MDRE infections, respectively.
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Table 4: Enterobacteriaceae isolates among patients with MDRE and non-MDRE UTIs:
University of Gondar Hospital, February to May 2014.
Of the 183 Enterobacteriaceaeisolates, 160 (87.4%) were MDR strains, and these strains were
tested for carbapenemase production by using phenotypic methods (CHROMagar KPC media).
A total of 5 bacterial strains were found to be CPE, Notably E.coli (2), K. pneumoniae (2) and E.
aerogenes (1) (Figure 4). The overall prevalence of CPE was 2.73% (95%CI; 0.5-5.5%) among
all isolates and 3.1% among MDRE isolates, 4/5 (80%) of CPE isolates were identified from
females and 3/5 (60%) isolates were also indicated from patients with age group from 31 – 45
years (Table 3).  Besides, all CPE strains were 100% ESBL producer, which were demonstrated
by using phenotypic methods (CHROMagar ESBL media).
Isolates MDRE isolates (N = 160) Non-MDRE isolates (N = 23) P- value
E.coli 104 (65% ) 8 (34.8%) 0.020
K.pneumoniae 28 (17.5%) 1 (4.3%) 0.106
K.ozaenae 6 (3.8%) 2 (8.7%) 0.282
K.oxytoca 3 (1.9%) 0 (0.0) ___
E.aerogenes 12 (7.5%) 1 (4.3) 0.582
E.cloacae 1 (0.63%) 2 (8.7%) 0.004
P.mirabilis 0 (0.0) 5 (21.7%) ___
P.vulgaris 1 (0.63%) 3 (13%) <0.001
Citrobacter spp. 5 (3.13%) 1 (4.3%) 0.758
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Figure 4: Proportion of CPE from MDRE isolates among study participants: University of
Gondar Hospital, February to May 2014.
6.3. Risk factors for MDRE and CPE among study participants
Risk factors associated with MDRE UTIs were analyzed by comparing patients with and without
MDRE UTIs. By bivariate analysis (Table 5), age, hospitalization for the last 12 months, prior
urinary tract infection for the past 12 months, prior antibiotic use for the past 6 months were
associated with MDRE infections. In the multivariate logistic regression analysis (Table 5),
independent risk factors for MDRE were prior antibiotic use, and hospitalization since the past
12 months, age, and sex (female).
Risk factors for CPE among patients with UTIs were analyzed by comparing patients with and
without CPE. However, none of the investigated factors (age, hospitalization for the last 12
months, prior urinary tract infection, and prior antibiotic use) were found as risk factor for CPE
among patients with UTIs.
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Table 5: Risk factors associated with MDRE among study participants: University of Gondar
Hospital, February to May 2014.
Risk factors MDRE Bivariate analysis Multivariable analysis
Yes
(N = 160)
No
(N = 23)
COR
(95% CI)
P-value AOR
(95% CI)
P-
value
Sex
Female 106 12 1.79 (0.75 – 4.34) 0.191 4.46 (1.29 – 15.35) 0.018
Male 54 11 1 1
Age (years)
Mean age 38.5 13.2 1.08 (1.05 - 1.12) < 0.001 1.08 (1.03 – 1.13) 0.001
Hospitalization
Yes 114 9 3.86 (1.56 – 9.53) 0.003 5.22 (1.59 – 17.17) 0.006
No 46 14 1 1
Prior UTI
Yes 65 4 3.25 (1.06 – 9.99) 0.040 2.41 (0.56 – 10.34) 0.239
No 95 19 1 1
Prior antibiotic use
Yes 129 7 9.51 (3.60 – 25.11) < 0.001 3.98 (1.056 – 14.97) 0.041
No 31 16 1 1
Note that: COR: crude odds ratio, AOR: adjusted odds ratio, CI: confidence interval
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6.4. Antibiotic resistance pattern of MDRE and CPE among study participants
The overall resistance profile of MDRE isolates are shown in Table 6. High resistance rate were
observed to ampicillin (97.5%) followed by cotrimoxazole (64.4%), and chloramphenicol
(61.2%). Whereas, ciprofloxacin, cefepime, and ceftriaxone had an overall resistance rates of
2.5%, 10.6%, and 11.9%, respectively. Species specific antibiotic resistance rates are also
presented in Table 6. E.coli, the most frequently isolated bacterium, showed that more than 55%
of strains were resistant to ceftazidime, gentamycin, chloramphenicol, cotrimoxazole, and
ampicillin and low rates of resistance rates were noted to ciprofloxacin (1%), cefepime (8.7%)
and ceftriaxone (11.5%). K. pneumoniaethe second most common isolate exhibited over 60% of
strains were resistance to amoxicillin-calvulanic acid, chloramphenicol, cefpodoxime, and
ampicillin, relatively low resistance rates were indicated to ciprofloxacin (10.7%), cefepime
(14.3%), and ceftriaxone (17.9%).
Additionally, the overall resistance pattern of CPE isolates are summarized in Figure 5. All
isolates were 100% resistant to cefotaxime, cefpodoxime, cotrimoxazole, chloramphenicol,
ampicillin, and amoxicillin-calvulanic acid. However, only 20% of strainswere resistant to
ciprofloxacin. Moreover, as shown from Figure 5, the overall antibiotic resistance rates of CPE
isolates were significantly higher than other MDRE strains for more than half of tested
antibiotics including cefotaxime (100% versus 22.6%; P<0.001), ceftriaxone (60% versus 10.3%;
P=0.001), cefpodoxime (100% versus 42.6%; P = 0.011). On the other hand the difference in
antibiotic resistance rate of CPE to ceftazidime, tetracycline, cotrimoxazole, chloramphenicol,
ampicillin, and gentamycin were not statistically significant compared to other MDRE isolates.
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Table 6: Antibiotic resistance patterns of MDRE among study participants: University of Gondar Hospital, February to May 2014.
MDR isolates Antibiotics
CTX CAZ CTR CPD CPM CIP TE SXT C AMP NA GEN AMC
E.coli(N=104) 25
(23.1)
58
(55.8)
12
(11.5)
43
(41.3)
9
(8.7)
1 (1) 49
(47.1)
72
(69.2)
61
(58.7)
103
(99)
19
(18.3)
59
(56.7)
47
(45.2)
K.pneumoniae(N = 28) 8
(28.6)
16
(57.1)
5
(17.9)
18
(64.3)
4
(14.3)
3
(10.7)
15
(53.6)
14
(50)
18
(64.3)
26
(92.9)
7 (25) 16
(57.1)
17
(60.7)
K. ozaenae  (N = 6) 1
(16.7)
4
(66.7)
0 3 (50) 0 0 4
(66.7)
5
(83.3)
5
(83.3)
6
(100)
2
(33.3)
4
(66.7)
5
(83.3)
K. oxytoca (N = 3) 1
(33.3)
2
(66.7)
0 1
(33.3)
1
(33.3)
0 1
(33.3)
2
(66.7)
2
(66.7)
3
(100)
1
(33.3)
3
(100)
1
(33.3)
E. aerogenes (N = 12) 4
(33.3)
7
(58.3)
2
(16.7)
5
(41.7)
3 (25) 0 5
(41.7)
5
(41.7)
7
(58.3)
12
(100)
2
(16.7)
7
(58.3)
9 (75)
E. cloacae (N = 1) 1
(100)
1
(100)
0 0 0 0 0 1
(100)
0 1
(100)
0 0 0
Citrobacter spp (N = 5) 1 (20) 2 (40) 0 1 (20) 0 0 4 (80) 3 (60) 4 (80) 4 (80) 1 (20) 4 (80) 2 (40)
P. vulgaris (N = 1) 0 0 0 0 0 0 1
(100)
1
(100)
1
(100)
1
(100)
0 1
(100)
0
Total (N = 160) 40
(25)
90
(56.2)
19
(11.9)
71
(44.4)
17
(10.6)
4
(2.5)
79
(49.4)
103
(64.4)
98
(61.2)
156
(97.5)
32
(20)
94
(58.8)
81
(50.6)
Note: Data are in number (%) unless otherwise indicated.
CTX: Cefotaxime, CAZ: Ceftazidime, CTR: Ceftriaxone, CPD: Cefpodoxime, CPM: Cefepime, CIP: Ciprofloxacin, TE: Tetracycline, SXT:
Cotrimoxazole, C: Chloramphenicol,NA: Naldixic acid, GEN: Gentamycin, AMC: Amoxicillin-Calvulanic acid.
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Antibiotics
CTX CAZ CTR CPD CPM CIP TE SXT C AMP NA GEN AMC
P-valuea <0.001 0.277 0.001 0.011 <0.001 0.011 0.629 0.091 0.071 0.716 0.023 0.327 0.025
Note that: a: compared between CPE and other MDRE
CTX: Cefotaxime, CAZ: Ceftazidime, CTR: Ceftriaxone, CPD: Cefpodoxime, CPM: Cefepime, CIP: Ciprofloxacin, TE: Tetracycline, SXT:
Cotrimoxazole, C: Chloramphenicol,NA: Naldixic acid, GEN: Gentamycin, AMC: Amoxicillin-Calvulanic acid.
Figure 5: Antibiotic resistance rate of CPE isolates compared to other MDRE among study participants: University of Gondar
Hospital, February to May 2014.
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7. DISCUSSION
The present study showed that the prevalence of MDR among Enterobacteriaceae isolates
identified from patients with symptomatic UTI was 87.4% (95% CI; 82-92.3%), which is slightly
similar with the results reported in Gondar (85.5%) and Mozambique (88.2%) (21, 24). While,
relatively low prevalence of MDR uropathogens weredemonstrated in Ethiopia;Gondar (68%),
and Dessie (74.6%) (23, 26). Moreover, the present result is also much higher than reports from
other countries, such as Chicago (19.06%), Belgium (62%), and Italy (62%), Nepal (40.1%,
64.04%) (16-20). However, it is lower than reports in other studies from Gondar (93.5%),
Bahirdar (95.6%), and Jimma (100%) (25, 27, 28). We postulate that, variation in prevalence of
MDRE could be due to increase trend of MDR strains with time, and difference in geographical
location, study period, study population, study design, method employed for each study.
E.coli (65%) and K. pneumoniae (15.6%) are the principal MDR isolates in this study, which are
comparable with other previous studies conducted in different part of Ethiopia, i.e. Gondar,
Dessie, Bahirdar and Jimma (25–28).  Likewise the finding from Nepal, E.coli (74%) and
K.pneumoniae (44%) were also the predominant MDR uropathogens (20), the same situation
also demonstrated in Senegal, Chicago, Italy, and Belgium (16–18, 22). However, another study
in Nepal showed that Citrobacter spp. (72%) were the main MDR isolate (19), which were the
least resistant uropathogens determined by this study.
Furthermore, in this study most of MDRE showed less susceptibility pattern to many of tested
antibiotics. Particularly, resistance pattern were alarmingly higher for ampicillin (97.5%),
cotrimoxazole (64.3%), chloramphenicol (61.2%), gentamycin (58.7%), ceftazidime (56.3%),
amoxicillin-calvulanic (50.7%) and tetracycline (49.4%). Enterobacteriaceaeisolates were
appeared about twice more resistant to cefpodoxime than to naldixicacid (44.4% vs 20%), and
twice more susceptible to cefotaxime than amoxicillin-calvulanic (50% vs 24.4%) and
gentamycin (50% vs 27.5%).   On the other side, majority of MDR isolates showed susceptibility
tociprofloxacin (90.6%), followed by cefepime (67.5%) and ceftriaxone (66.9%). Despite
variation in proportion of resistant strains, similar circumstance of resistance pattern were also
reported in Senegal, 77.3%, 55%, 14.7%, 13.3% of MDR isolates were resistant to ampicillin,
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cotrimoxazole, amoxicillin-calvulanic acid and naldixic acid, respectively (22). As general point,
most documented finding claimed that rate of antibiotic resistant drastically elevated, despite
difference in magnitude of drug resistance. This might be attributed by policies on drug
prescription, variability of guidelines for antibiotic prophylaxis or empiric treatment, variation in
study population, geographical location, and socio-economical factors.
According to world health organization, 2014 report, in most of developed countries, the
epidemiology of CPE isolates have frequently elucidated, whereas in others including African
countries no sufficient epidemiological information is available, therefore the report insisted that
integrated surveillance program and involvement of very active investigators have to be
maximized in order to know the extent of resistant strainsin developing countries. Even though
carbapenems drugs are not formally introduced in to Ethiopia, as the report claimed that increase
international travel, globalization, migration, and medical tourism, might have contributing role
in the dissemination of resistant strains from potentially risk countries (59). Particularly, in our
study area, there is high tourist flow, andmany of residences have Diasporarelatives from abroad
especially United States of America, which may have an impact on the emergence of
carbapenemase producing, strains in this locality.
As revealed from the present study, out of 183 Enterobacteriaceae isolates, 2.73% (95% CI, 0.5 –
5.5%) were found to be carbapenemase producers among species isolated from patients with
symptomatic UTIs. A comparable incidence of CPE were reported in studies Morocco (2.8%)
(49), Bangladesh (4.8%) (43), Taiwan (2.5%) (46), Belgium (3.5%) (36), and India (5.4%) (40).
while, other studies revealed that relatively high prevalence of CPE were investigated in Pakistan
(8.6%) (42), Turkey (10.9%) (38), India (12.9%) (41), Nigeria (14%, 33.5%) (47, 48), Iran
(14.5%) (45), and United States of America (21%) (39).
The difference in the incidence of CPE among published data and the present study might be due
to trends in the utilization of carbapenems and other broad spectrum antibiotics,
cultural/traditional relationships, exchange of population with other countries of high prevalence,
cross boarder transfer of patients, travel, medical tourism, and refugees. Additionally, difference
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in target study population, sample size variation, methodological variability could result
variation in the epidemiology of CPE.
According to EARS surveillance study, many of carbapenemase producers were K. pneumoniae
followed by E.coli andEnterobacter spp., the rest were other Enterobacteriaceae isolates(33).
The same situations were also notified in finding from Turkey and Moroccoindicated that K.
pneumoniae were the principal isolate followed by E.coli and K.oxytoca were important species
of carbapenemase producer (38, 49).  In spite of similarity among carbapenemase producer, but
the proportion of isolates is incomparable to our study.  We attested that 5 Enterobacteriaceae
isolates were found to be carbapenemase producernamely;2 E.coli, 2 K. pneumoniae, and 1 E.
aerogenes.  On the other hand, a study from Nigeria demonstrated that E.coli was the main
carbapenemase producer followed by Proteus spp. and K. pneumoniae (48). The variation among
studies with regard to the proportion of carbapenemase producing isolates; could be due to
difference in geographical distribution of isolates, target study population, sample size, and
methodology used in each investigation.
Carbapenemase producing Enterobacteriaceae are extremely resistant to almost all available
drugs in the market, including β-lactam and non β-lactam antibiotics (6), instantaneously this
circumstance was also demonstrated in our study.  Therefore, we tried to explore the antibiotic
resistance pattern of CPE; hence all CPE isolates showed resistance to many of antibiotics, 100%
resistance to cefotaxime, cefpodoxime, cotrimoxazole, chloramphenicol, ampicillin, and
amoxicillin-calvulanic acid; 80% resistance to ceftazidime, and gentamycin; 60% resistance to
ceftriaxone, cefepime, tetracycline, and naldixic acid. Interestingly, 60% of isolates were
susceptible to ciprofloxacin, the reason mightbe due to carbapenemase producer are primary
active against β-lactam drugs; even though, some of isolates co-expresses other resistance
mechanisms to non β-lactam agents (quinolone, aminoglycosides).
In agreement to our study, finding from Kenya advocated that all carbapenemase producers were
100% resistant to b-lactam agents, non b-lactam agents (aminoglycosides, fluoroquinolones,
chloramphenicol, sulfonamides) and including carbapenems (51). Similarly a study from
Morocco also documented that the isolates were 100% resistant to amoxicillin-calvulanic acid,
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cefotaxime , ceftriaxone, and cotrimoxazole, but gentamycin resistance decreased by half, and
ciprofloxacin resistance increased almost by 2 times as compared to our finding(49). Those
discrepancies might be variation in study population, standards employed for the interpretation
of antimicrobial susceptibility testing.
In Bivariate analysis, age (years), hospitalization withinthe past 12 months, prior antibiotic
therapy in the past 6 months, and prior UTI in the past 12 months were associated with MDRE
UTI in this study. Likewise, in multivariable analysis, age, being female, hospitalization within
the past 12 months, and prior antibiotic use in the past 6 months were the independent risk
factors for MDRE UTIs.  The same scenario also documented in a study in Chicago (16), showed
that the above specified risk factors were also associated with MDRE UTIs. However, additional
risk factors like health care associated risks (use of urinary catheter, mechanical ventilation, and
hemodialysis) were identified in the former study, which were not indicated in this study. The
reason could be due to variation in sample size, study design, geographical area and study
population.
Moreover, this study also emphasized to assess risk factors associated with the colonization of
CPE. However, none of the factors (age, sex, hospitalization, prior antibiotic use) were
associated. This finding is completely disagree from result provided by several literatures, for
instance based on ECDC report, advanced age, prior antibiotic use, hospitalization, chronic
diseases (HIV/AIDS, diabetes mellitus), ICU admission and health care associated factors were
associated with CPE infection (52). We suggested that such difference could be due to rare
nature of the incidence and requires large scale study in order to point out risk factors. Besides,
this is the first time investigation, and difficult to indicate all possible circumstances, which are
directly or indirectly linked to CPE colonization. The present study only includes patients with
symptomatic UTI; this is also the main thing for difficulty to pick up truly associated variables as
mentioned by previous studies.   Furthermore, study design variation may also attribute for this
outcome presented by our study.
33
8. LIMITATION OF THE STUDY
In the present study, investigation of CPE was determined by using phenotypic methods, but
could be better when it is supplemented by molecular techniques, which are essential to
characterize the specific types of carbapenemase.
9. STRENGTH OF THE STUDY
This is a timely study, since antibiotic resistance becoming an alarming problem in both
developed and developing world. Therefore, our study is perhaps the first one to identify new
drug resistance mechanisms via the production of carbapenemase among Enterobacteriaceae
uropathogens; which were not studied in our country at all.
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10. CONCLUSION
The finding demonstrated that, high rates of drug resistance were observed among
Enterobacteriaceae uropathogens, taking resistant two or more drugs; it was detected in 87.4% of
isolates, E. coli and K. pneumoniae were the principal MDR isolates. Multidrug resistant
Enterobacteriaceaeexhibited high drug resistance rates to ampicillin, followed by cotrimoxazole
and chloramphenicol. Sex (female), age, hospitalization, and prior antibiotic use were
independent risk factors for MDRE.Moreover, in the present study new drug resistance
mechanisms via carbapenemase production among five Enterobacteriaceae isolates were
detected. The isolates were completely resistant to ampicillin, cefotaxime, cefpodoxime,
cotrimoxazole, chloramphenicol, and amoxicillin-calvulanic acid, only ciprofloxacin had showed
low resistance rate to those strains, besides these isolates were found to be 100% ESBL
producer.
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11. RECOMMENDATIONS
Based on this finding the following recommendations are put forward to
Governmental bodies (hospital administrators)
1. Should take direct responsibility to facilitate periodic surveillance to control and
prevent the emergence of MDR strains
2. Re-enforcement of local microbiology laboratories for the detection of CPE should be
promotedthrough introduction of new methodologies.
Health professionals
1. Multidisciplinary approach is required in order to reduce patient hospital stay, and for
appropriate prescription of antibiotics.
2. Should pay special attention to elderly and female patients, since those groups easily
vulnerable to acquire infection caused by MDR  strains
Researchers
1. Meticulous scientific and medical research, especially on CPE is so substantial, which
includes using relatively standard methods,  large study population and geographical
area should be considered
2. Trends in the prevalence, and antibiotic resistance pattern of Enterobacteriaceaeshould
continually reassessed through rigorous scholar findings
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13.ANNEXES
Annex I: QUESTIONNAIRE& LABORATORY DATA COLLECTION FORM
Interviewer administered questionnaire (to be filled by health professionals): Patient ID___
Aim of the study: to assess the prevalence and risk factors of multidrug resistant and
carbapenemase producing Enterobacteriaceae among patients with urinary tract infection.
Section 1: DEMOGRAPHIC INFORMATION:
Section 2: CLINICAL INFORMATION
S.no Questions Code Response
1. Sender of the patient 1 = outpatient , 2 = inpatient
2. If in patient , Name of admission ward: __________ Date of admission: _______________
3. Admitted to this health care facility from 0 = home
1 = other hospital/health center
4. If the response is admission from other hospital/health center, name________________
5. Did you have a history of travel abroad in
the last 12 months prior to hospitalization
0 = No
1 = yes
6. If yes: name of the country ________________________________
S.no. Question Code Response
1. Sex 0 = Male, 1 = Female
2. Age ______________ years
3. Nationality ______________________
4. Residence 1 = Urban
2 = Rural
5. Education status 0 = illiterate, 1 = Primary
school, 2 = Secondary
school, 3 = diploma & above
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7. State the reason for travel abroad 1 = holiday, 2 = work, 3 =
medical intervention, 4 = visiting
friends & relatives, 5 = other
Section 3: RISK FACTOR FOR MDRE/CPE: please tick a code that apply to this patient
S.no Questions Code Response
1. Did you have  history of hospitalization in the past 12 months 0 = No, 1= Yes
2. Did you have history of ICU admission in the past 12 months 0 = No, 1= Yes
3. Did you have history of UTI infection past 12 months 0 = No, 1= Yes
4. Did you have history of suffering with disease/infection
condition (UTI, meningitis, pneumoniae, wound, bacteraemia,
peritonitis, tuberculosis, GIT infection, and other infection
mainly caused by bacteria) the past 12 months
0 = No
1= Yes
5. If yes, did you have history of antibiotic therapy for the
specified disease/infectionsince the past 6 months
0 = No
1= Yes
6. Did you have  history of using urinary catheter in the past 12
months
0 = No, 1= Yes
7. Did  you have  history of using mechanical ventilation/
breathing machines in the past 12 months
0 = No
1= Yes
8. Did you have history of surgery in the last 6 months 0 = No, 1= Yes
9. Are you  pregnant 0 = No, 1= Yes
10. Did you have history of hemodialysis in the last 3 months 0 = No, 1= Yes
44
Part II. LABORATORY DATA COLLECTION FORM
S.no Question Code Response
1. Does Enterobacteriaceaeisolated 0 = No, 1 = yes
2. Type of Enterobacteriaceaeisolated
1. E. coli, 2. K. pneumoniae, 3. K.
ozaenae, 4. K. oxytoca, 5. E. aerogenes, 6.
E. cloacae, 7. P. mirabilis, 8. P.vulgaris,
9. Citrobacter spp.
3. MDRE organism isolated 0 = No, 1 = Yes
4. CPE Organism isolated 0 = No, 1 = Yes
5. Antibiotic Susceptibility Pattern:
Name of Antibiotics
Sensitivity Results (CLSI, 2013): Zone diameter breakpoints nearest to whole mm
Disc
content
Susceptible
(S)
Intermediate
(I)
Resistant
(R)
Zone
Reading(mm)
RESULT (S or
I or R)
Cefotaxime (CTX) 30µg
Ceftazidime (CAZ) 30µg
Ceftriaxone (CTR) 30µg
Cefpodoxime (CPD) 30µg
Cefepime (CPM) 30µg
Ciprofloxacin (CIP) 5µg
Tetracycline (TE) 30µg
Trimethoprim-
sulphamethaxzole (SXT)
25µg
Chloramphenicol (C) 30µg
Ampicillin (AMP) 10µg
Naldixic acid (NA) 30µg
Gentamycin (GEN) 10µg
Amoxicillin-calvulanic
acid (AMC)
30µg
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Annex II: Urine collection and processing
Specimen collection: First morning specimens yield highest bacterial counts from overnight
incubation in the bladder, and are the best specimens.
Procedure for midstream urine for bacterial investigation
1. Give the patient suitable container
2. Instruct the patient before the collection, preferably with illustration.
3. Tell the patient not to touch the inside or rim of the container
 Male
 If not circumcised, draw back the foreskin
 Begin to urinate, but pass the first portion into the toilet.
 Collect the mid-portion of urine into the container, and pass the excess into the toilet.
 Female
 Squat over the toilet and separate the labia with one hand.
 Void the first portion of urine into the toilet.
 Collect the mid-portion of urine into the container and pass the excess into the toilet.
 Infants:Have ready: Clean, preferably sterile container of appropriate size or aplastic bag,
cotton wool or gauze pads, hand warm soapy water.
 Clean the external genitals.
 Give the child as much liquid as possible just prior to the collection
 Seat the child on the lap of the mother, nurse or ward attendant
 Collect as much urine as possible in the container or plastic bag when theinfant
urinates.
Processing: approximately 20ml of urine sample is required; the maximum time allowed for
processing a urine sample is 2 hours from the time of collection. If delay is inevitable, should be
refrigerated / preserved (boric acid). During culturing, the urine must be re-suspended and streak
1µl of the volume to blood agar. After overnight incubation plate count of 100,000 CFU/ml of
pure culture should be considered positive and isolated organism should be identified and
sensitivity test will be performed.
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Annex III: urine culture for isolation of MDR &CPE
Urine culture on blood agar plate
 Dips the 0.001 ml loop into the urine same (just into the urine,
without submerging the plastic sample).
 Place a straight line down the center of the agar plate, then
streak in a dense zigzag pattern back and forth across the plate
to the bottom.
 Overnight Incubation at 37oc
 Check for growth, calculate the number of bacteria in the
urine sample = no of colony count x dilution of calibrated
loop (1000)
 If it is > 105/ml of urine, gram staining will be done to decide
the predominant colony type (gram –ve  or gram +ve bacteria)
MacConkey agar for gram –ve rod
bacteria
 Sub-culture pure colonies from BAP to
MAC.
 Overnight Incubation at 37oc
 Check for growth, and lactose
fermentation
 Perform biochemical test for
Enterobacteriaceae identification
Biochemical tests for Enterobacteriaceae
Isolate TSI Gas prod. H2S prod. Indole citrate urea motility Lysine dec
E.coli A/A + - + - - + +
Citrobacter spp A/A + + - + +/- + -
K. pneumoniae A/A + - - + + - +
K. oxytoca A/A + - + + + - +
E. aerogenes A/A + - - + - + +
E. cloacae A/A + - - + +/- + -
P. mirabilis Ak/A + + - +/- + +++ -
P. vulgaris A/A +/- + + -/+ + +++ _
Antimicrobial susceptibility testing on Muller Hinton agar
 Take 3 – 5 pure colonies of the isolate and suspend in
nutrient broth
 Adjust the turbidity of the broth with 0.5% barium
sulphate solution
 Dip a sterile cotton swab into the broth suspension. Rotate
the swab several times on the inside wall of the tube above
the fluid level to remove excess inoculum from the swab
 Inoculate the surface of the plate by streaking the swab
over the surface of the plate 2/more times.
 Place the appropriate discs onto the respective cultures.
Deposit discs so that the centers are at least 24 mm apart.
 After overnight incubation, measure zone of inhibition to
the nearest mm. report as resistant, intermediate, &
susceptible according to CLSI guidelines
Isolation of CPE using CHROMagar KPC
medium
 Pure colonies of MDRE isolates will be
inoculated to the agar plate
 After overnight incubation, CPE will produce
colonies with typical coloring features.
Quality control strains
K. pneumoniae ATCC 1705 ------- steel blue
S. aureus ATCC 25293--------- inhibited
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Annex IV: patient information sheet and consent form
Patient information sheet
Study title: Prevalence and risk factors of multidrug resistantand carbapenemase
producing Enterobacteriaceaeamong patients with urinary tract infection,
Gondar University Hospital, North west Ethiopia.
Locality: University of Gondar:
department of Medical
Microbiology
Ethics committee: UOG
Lead
investigator:
Setegn Eshetie(BSc.) Contact phone
number:
0913151163
You are invited to take part as a study participant in the research conducted by MSc candidate in
University of Gondar.  Whether or not you take part is your choice.  If you don’t want to take
part, you don’t have to give a reason, and it won’t affect the care you receive.  If you do want to
take part now, but change your mind later, you can pull out of the study at any time.
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out why
we are doing the study, what your participation would involve, what the benefits and risks to you
might be, and what would happen after the study ends.  We will go through this information with
you and answer any questions you may have.    You do not have to decide today whether or not
you will participate in this study. Before you decide you may want to talk about the study with
other people, such as family, friends, or healthcare providers.  Feel free to do this.
If you agree to take part in this study, you will be asked to sign the Consent Form on the last
page of this document.  You will be given a copy of both the Participant Information Sheet and
the Consent Form to keep. This document is 3 pages long, including the Consent Form.  Please
make sure you have read and understood all the pages.
Purpose of the study: emergence of drug resistance among bacteria, especially in
Enterobacteriaceae is a major public health treat.  Knowledge about current prevalence of
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carbapenemase producing and MDRE, associated risk factors is so substantial to design possible
intervention and preventive strategies. Hence the aim of this project is to explore prevalence and
risk factors ofMDREand carbapenemase producing strains.
Procedure: In order to perform the indicated study at Gondar university hospital you are invited
to take part in this project. If you are willing to participate, you need to understand the purpose of
the study and give your consent. The required clinical sample will be collected by you.For
severely ill patients, infants, the sample collection may aided by health care providers/ families.
Possible risks/discomfort: There are no anticipated risks to your participation. Sample
collection for severely ill patients may require urinary catheter, in such procedure you may feel
some discomfort. But this not predisposes you to unwanted problems.
Benefits of study: you will be treated accordingly as result of diagnosis procedure.
Instantaneously; after completion of this study, it provides millstone information to design
preventive and control measures so that the society will be benefited from the outcome of study.
Compensation for participation: You will not receive any payment for your participation in
this research study.
Confidentiality: There is no sensitive issue that you will be asked related with your social
desirability but any information that is obtained in connection with this study and that can be
identified with you will remain confidential. The information collected about you will be coded
using numbers.
Participation and withdrawal: You can choose whether to be a part of this study or not. You
may withdrawal at any time without consequences of any kind. You may also refuse to give any
sample.
Person to contact: If you have any question you can contact any of the following (Investigator
and Advisors) and you may ask at any time you want.
Setegn Eshetie: Cell phone: 0913151163, E-mail: seteeshetu@yahoo.com, Face book: Sete
Eshetu
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Patient consent form (> 18 years of age)&able to respond
I have read, or have had this document read to me in a language that I understand, and I
understand the purposes, procedures and risks of this research project as described within it.
I have had an opportunity to ask questions and I am satisfied with the answers I have received.
I freely agree to participate in this research project, as described.
I understand that I will be given a signed copy of this document to keep.
Participant’s name ……………………………………………………
Signature Date
For families or attendants of patients unable to respond
I______________________________________ parent/guardian/attendant, after being fully
Informed about the purpose of this study, hereby give my consent on the patient’s Participation
in this study. I understand that my child free to withdraw at any time without penalty or loss of
benefits.
Signature of first parent or guardian __________________________    date _______________
Declaration: I have given a verbal explanation of the research project, its procedures, other
related issues and I believe that the participant has understood that explanation.
Researcher’s name:  Setegn Eshetie
Signature Date
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አማረኛ ትርጉም (version)
መድሀኒት መቋቋም የሚችሉና በተለይም ካርፓፔንሜዝ የሚባል እንዛይም የሚፈጥሩ
ተዋስያንበማስመልከት፣ በተጨማሪም የተለያዩ የሚያጋልጡ ሁኔታዎችን ለማጥናት በሽንት
ፊኛ ታካሚዎች ላይ የተዘጋጀ መጠይቅ ነው፡፡
መመሪያ (በጤና ባለሞያዎች የሚሞላ): እባክዎን ከዚህ በታች ለተዘረዘሩ ጥያቂዎች ከፊት
ለፊት ከተቀመጡት ምርጫወች ታካሚውን በመጠየቅ፤ በመመልከት እና ሌሎች
መረጃዎችን በመውሰድ (medical record, clinical & laboratory diagnosis)በተዘጋጀው
ሳጥን ምልክት በማድረግ እና ክፍት ቦታወችን በፅሁፍ በመግለጥ መልስ ይስጡ::
ክፍል አንድ:አጠቃላይ ማህበራዊ ነክ መረጃዎችን ለመዳሰስ የተዘጋጅ፡፡ የታካሚው ኮድ---
ተ/ቁ ጥያቄ ኮድ መልስ
1. ፆታ 1 = ወንድ፣ 2 = ሴት
2. እድሜ፡ ----------------------------------------አመት
3. ዜግነት፡ ----------------------------------------
4. መኖሪያ በታ 1 = ከተማ ፣ 2 = ገጠር
5. የት/ት ሁኔታ 0= ያልተማረ፣ 1 =1ኛ ደረጃ ያጠናቀቀ፡ 2 = 2ኛ ደረጃ
ያጠናቀቀ፣ 3 = ከዚያ በላይ
ክፍል ሁለት፡ አጠቃላይ የህክምና መረጃዎችን እና ሌሎች ተዘማጅ ሁኔታዎች ለመዳሰስ
የተዘጋጀ
1. የሕክምና ሁኔታ 1 =ተኝቶ የሚታከም፤
2=ተመላላሽ
2. ተኝቶ የሚታከም/የምትታከም/ ከሆነ የዋርዱ ስም -----------------የተኛበት/የተኛችበት/ ቀን-----
------------
3. ወደ ሆስፒታሉ የመጡት ከሌላ ጤና
ድርጅት ሲታከሙ ቆይተው ነው
1 = አወ፡ 2 = አይደለም
4. ከአንድ አመት በፊት ወደ ሌላ ሀገር
ሂደው ያወቃሉ
1 = አወ፡ 2 = አይደለም
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5. አወ ካሉ የት ሀገር -----------------------------------------------
6. የሄዱበት ምክንያት ለምንድን
ነው፡
1 = ዘመድ ለመጠየቅ፤2 = ለህክምና፡
3=ለጉብኝት፤ 4 =ለስራ፤ 5 =ለበአል ፤6
=ሌላ ካለ ይጥቀሱ
ክፍል 3፡ ከዚህ በታች የተዘረዘሩት ሁኔታዎች ታካሚውን የሚጠቅስ ከሆኑ ከፊት ለፈት
በተዘጋጀው ሳጥን ምልክት
1. ከዚህ በፍት በ ጤና ድርጅት ውስጥ ተኝተው
ታክመው ያውቃሉ
1 =አዎ፤ 2 = አይደለም
2. ከዚህ በፊት ህይወትዎን ለአደጋ የሚጥል
አደጋ/በሽታ ተጋልጠውና ታክመው ያውቃሉ
1 =አዎ፣ 2 = አይደለም
3. የቀዶ ጥገና ህክምና ተደርጎዎለት ያወቃል ወይ 1 =አዎ፣ 2 = አይደለም
4. በሽተኛው ኤች አይቪ/ኤድስ በደሙ/ሟ ዉስጥ
ተገኝቷል ወይ (በጤና ባለሙያ የሚመለስ)
1 =አዎ፣ 2 = አይደለም
5. የወለድ መቆጣጠሪያ ተጠቅመው ያውቃሉ 1 =አዎ፣ 2 = አይደለም
6. የስኳር በሽታ ተጠቂ ነዎት ወይ (በህክምና ምርመራ
ወይም በተጠያቂው የሚመለስ)
1 =አዎ፣ 2 = አይደለም
7. ነፍሰ ጡር ነዎት ወይ (በህክምና ምርመራ ወይም
በተጠያቂው የሚመለስ)
1 =አዎ፣ 2 = አይደለም
8. ከ አሁን በፊት የተለያዩ መድኒቶችን ለፀረ-
ተዋህሲያን ተጠቅመው ያውቃሉ
1 =አዎ፣ 2 = አይደለም
9. ከአሁን በፊት የሽት ፊኛ ህመም ታመው ያውቃሉ 1 =አዎ፣ 2 = አይደለም
10. የሽንት መሽኛ ትቦ ተደርጎወለት ያውቃል ወይ 1 =አዎ፣ 2 = አይደለም
11. የአየር መተንፈሻመሳሪያ ተደርጎዎለት ያወቃል 1 =አዎ፣ 2 = አይደለም
12. የደም ማጥራት ህክምና ተደርጎዎለት ያወቃል ወይ 1 =አዎ፣ 2 = አይደለም
13. ከላይ የተጠቀሱት አጋላጭ ሁኔታዎች የሉበኝም 1 =አዎ፣ 2 = አይደለም
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የጥናቱ ማብራሪያና ስምምነት ቅጽ
1. ጥናቱን የሚያካሂደው ሰው ስም
ሰጠኝ እሸቴ (የመጀመሪያ ዲግሪ ምሩቅና በጎንደር ዩንቨርስቲ የሁለተኛ ዲግሪ ተማሪ)
2. የጥናቱ ዓላማ
ጥናቱ ¾T>"H@Å¬ ¾i”ƒ ò— ISU }Öm uJ’<“ uÔ”Å` ¿”y`e+ Jeúታል}Ñ˜}¬
uT>ŸS<ui}™‹ LÃ c=J” ¯LT¬ SÉሀኒት የመቋቋም ብቃት ያላቸውን
v¡‚]Á­‹”SK¾ƒ“በተለይም ካርፓፔንሜዝ የሚባል እንዛይም በሚፈጥሩ
ተዋስያንበማስመልከት; እና ተዛማጅ አጋላጭ ምንገዶችን ለይቶ ለማውጣት ነው፡፡
3. uØ“~ eKSd}õ
u²=I Ø“ƒ Sd}õ uS<K< ðnÇ˜’ƒ LÃ ¾}Sc[} ’¬:: eKJ’U uØ“~ ›”Ç=d}ñ
ðnÅ˜’ƒ­” እ”ÖÃnK”:: uØ“~ K=d}ñ Ÿ}eTS< NŸ=S< ¨ÃU ª“¬ }S^T]
KT>ÖÃp­ƒ ØÁo­‹ SMe SeÖƒ ÃÖupw­ታM:: KU`S^ ¾T>J” i”ƒ“ ÅU
›=”Ç=¨cÉ ðnÅ­” እ”ÖÃnK”::
4. K=Ÿc~ ¾T>‹K< eÒ„‹
KØ“~ uT>¨cÉ “S<“ U¡”Áƒ ¾}K¾ ‹Ó` ›ÃŸcƒw­ƒU:: ¾“S<“ ›¨dcÆ
ui}—¬ K^c< wKA ŸT>cÖ¬ “S<“ ¾}K¾ ›ÃÅKU:: i”ƒ Si“ƒ
KT>Áp}†¨<ታካሚዎች ናሙናው በቱቦ በሚወሰድበት ጊዜ›”ÅT”—¬U ui}— ¾}KSÅ
+”i ›KSS‰†ƒ K}¨c’ Åmn K=•` Ã‹LM::
5. uØ“~ uSd}õ ¾T>Ñ˜ ØpU
ui}™‹ ŸU`S^¬ ¬Ö?ƒ kØ}— }ÖnT> ÃJ“K<:: ¾U`S^¬” ¬Ö?ƒ ŸGŸ=V‹
Ò` uS’ÒÑ` u›ÖnLÃ KQSU}™‹ uJeú}K< ¾}hK ð×” ›”¡w"u? KTÉ[Ó
ÁÓ³M::
6. ¡õÁ” u}SKŸ}
u²=I Ø“ƒ በSd}ፍዎ U”U ›Ã’ƒ ¡õÁ ›ÃŸðKዎƒU::
7. ¾Ø“~ S[Íዎ‹ T>eÖ=^©’ƒ
uØ“~ ¬eØ ¾}cucu< T“†¬U ÓL© S[Í­‹ T>eÖ=^©’ƒ ¾}Öuk ÃJ“M::
ŸT”’ƒ Ò` ukØታ }ÁÁ¶’ƒ ÁL†¬ S[Í­‹ uS<K< uª“ }S^T]¬ T>eÖ=^©
uJ’ ¾S[Í Ø”p` ²È Ÿ}k¾\ u%EL KU`U` H>Å~ w‰ ¾T>¬K< ¾J“K<::
8. ŸØ“~ eKS¬×ƒ“ eKTs[Ø
ÃI Ø“ƒ uõnÅ˜’ƒ LÃ ¾}Sc[} ›”ÅSJ’< SÖ” uT”—¬U ¨pƒ uðnÉዎ
ŸØ“~ S¬×ƒ Ã‹LK<::ŸØ“~ u=¨Ö<U ¾}KSÅ¬” ¾Q¡U“ እ`ÇታuÖ?“ }sS<
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¬eØ uT”—¬U Ñ>²? ¾TÓኘƒ Swƒ ›M­ƒ::
9. −Ÿƒ“~ Ò` u}ÁÁ² T“†¬U ØÁo u=•`  uT>Ÿ}K¬ ›É^h ØÁoዎ” Tp[w
Ã‹LK<:-
 cÖ˜ እሸቴ፡ ›É^h:- Ô”Å` ¿’>y`c=+ Q¡U“Ö?“ dÃ”e ó"M+& eM¡ 0913-
151163& ›=-T@ÃM: seteeshetu@yahoo.com
¾eUU’ƒ SÓKÝ pê
¾ui}—¬ UeÖ=` lØ`-------------
¾ui}—¬ S<K< eU-----------------------------------------
›’@ eT@ Ÿ²=I u²=‹ ¾}ÑKç¬ u²=I Ø“ƒ }dታò KSJ” e¨e” ¾Ø“~ ¯LT­‹
›c^a‹“pÉS G<’@­‹ uÓMê uS[Çƒ“ እ”Ç=G<U ŸØ“~ }d}ò’ƒ ðnÅ˜‚”
uT”—¬U Å[Í¾Te¨ÑÉ Sw‚” uT[ÒÑØ ’¬::
በ²=IØ“ት}d}ò SJ’@” uò`T¾ እÁ[ÒÑØŸ< ÃI”” e¨e” uጥ“~ du=Á K=Ÿc~
¾T>‹K< eÒ„‹” uT>Ñv ¾}[ÇG<“ ŸØ“~ uT”—¬U Å[Í ^c?” KTÓKM w¨e”
}Ñu= ¾J’< I¡U“ዎ‹“ እÑ³ዎ‹ G<K<እ”ÅTÃ’ðÑ<˜ uTS” ’¬:: እ’²=I S[Íዎ‹ G<K<
uT>Ñv uU[Ç¬ s”s ¾}ÑKèM˜ SJ’<” uò`TÂ ›[ÒÓ×KG<::
¾ui}—¬ S<K< eU----------------------------------------------------- ò`T--------------
¾}S^T]¬ S<K< eU------------------------------------------------ ò`T--------------
¾Ue¡` S<K< eU-------------------------------------------ò`T------------k”፡ -----/-----/-----
ለሕፃናትና ሀሳባቸውን መግለፅ ለማይችሉ አዋቂዎች አስታማሚዎች
እኔ ____________________________________________ የበሽተኛው አስታማሚ
ስሆን የዚህን ጥናት ዓላማ በውል በመገንዘብ በሽተኛው በጥናቱ እንዲሳተፍ የምስማማ
መሆኔን በፊርማዬ አረጋግጣለሁ፡፡
ፊርማ -----------------------------------------------------ቀን፡ -----/-----/-----
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